Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 289

1.

TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics.

Chou WC, Chou SC, Liu CY, Chen CY, Hou HA, Kuo YY, Lee MC, Ko BS, Tang JL, Yao M, Tsay W, Wu SJ, Huang SY, Hsu SC, Chen YC, Chang YC, Kuo YY, Kuo KT, Lee FY, Liu MC, Liu CW, Tseng MH, Huang CF, Tien HF.

Blood. 2011 Oct 6;118(14):3803-10. doi: 10.1182/blood-2011-02-339747. Epub 2011 Aug 9.

2.

TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.

Metzeler KH, Maharry K, Radmacher MD, Mrózek K, Margeson D, Becker H, Curfman J, Holland KB, Schwind S, Whitman SP, Wu YZ, Blum W, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD.

J Clin Oncol. 2011 Apr 1;29(10):1373-81. doi: 10.1200/JCO.2010.32.7742. Epub 2011 Feb 22.

3.

Landscape of TET2 mutations in acute myeloid leukemia.

Weissmann S, Alpermann T, Grossmann V, Kowarsch A, Nadarajah N, Eder C, Dicker F, Fasan A, Haferlach C, Haferlach T, Kern W, Schnittger S, Kohlmann A.

Leukemia. 2012 May;26(5):934-42. doi: 10.1038/leu.2011.326. Epub 2011 Nov 25.

PMID:
22116554
4.

Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.

Green CL, Koo KK, Hills RK, Burnett AK, Linch DC, Gale RE.

J Clin Oncol. 2010 Jun 1;28(16):2739-47. doi: 10.1200/JCO.2009.26.2501. Epub 2010 May 3.

5.

TET2 gene mutation is unfavorable prognostic factor in cytogenetically normal acute myeloid leukemia patients with NPM1+ and FLT3-ITD - mutations.

Tian X, Xu Y, Yin J, Tian H, Chen S, Wu D, Sun A.

Int J Hematol. 2014 Jul;100(1):96-104. doi: 10.1007/s12185-014-1595-x. Epub 2014 May 24.

PMID:
24859829
6.

TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.

Gaidzik VI, Paschka P, Späth D, Habdank M, Köhne CH, Germing U, von Lilienfeld-Toal M, Held G, Horst HA, Haase D, Bentz M, Götze K, Döhner H, Schlenk RF, Bullinger L, Döhner K.

J Clin Oncol. 2012 Apr 20;30(12):1350-7. doi: 10.1200/JCO.2011.39.2886. Epub 2012 Mar 19.

7.

Risk assessment in patients with acute myeloid leukemia and a normal karyotype.

Bienz M, Ludwig M, Leibundgut EO, Mueller BU, Ratschiller D, Solenthaler M, Fey MF, Pabst T.

Clin Cancer Res. 2005 Feb 15;11(4):1416-24. Erratum in: Clin Cancer Res. 2005 Aug 1;11(15):5659.

8.

[C-kit, NPM1 and FLT3 gene mutation patterns and their prognostic significance in 656 Chinese patients with acute myeloid leukemia].

Ding ZX, Shen HJ, Miao JC, Chen SN, Qiu QC, Qi XF, Jin ZM, Wu DP, He J.

Zhonghua Xue Ye Xue Za Zhi. 2012 Oct;33(10):829-34. Chinese.

PMID:
23384905
9.

IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.

Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Krönke J, Bullinger L, Späth D, Kayser S, Zucknick M, Götze K, Horst HA, Germing U, Döhner H, Döhner K.

J Clin Oncol. 2010 Aug 1;28(22):3636-43. doi: 10.1200/JCO.2010.28.3762. Epub 2010 Jun 21.

10.

DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications.

Hou HA, Kuo YY, Liu CY, Chou WC, Lee MC, Chen CY, Lin LI, Tseng MH, Huang CF, Chiang YC, Lee FY, Liu MC, Liu CW, Tang JL, Yao M, Huang SY, Ko BS, Hsu SC, Wu SJ, Tsay W, Chen YC, Tien HF.

Blood. 2012 Jan 12;119(2):559-68. doi: 10.1182/blood-2011-07-369934. Epub 2011 Nov 10.

11.

[The incidence of TET2 gene mutation and its clinical significance in acute myeloid leukemia patients].

Wei JF, Chen GH, Qiu HY, Fu CC, Ding ZX, Liu H, Feng YF, Chen SN, Chang WR, Wu DP.

Zhonghua Xue Ye Xue Za Zhi. 2011 May;32(5):304-7. Chinese.

PMID:
21729597
12.

Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia.

Steudel C, Wermke M, Schaich M, Schäkel U, Illmer T, Ehninger G, Thiede C.

Genes Chromosomes Cancer. 2003 Jul;37(3):237-51.

PMID:
12759922
13.

Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients.

Dufour A, Schneider F, Hoster E, Benthaus T, Ksienzyk B, Schneider S, Kakadia PM, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Braess J, Subklewe M, Hiddemann W, Bohlander SK, Spiekermann K; AML CG study group.

Ann Hematol. 2012 Jul;91(7):1051-63. doi: 10.1007/s00277-012-1423-4. Epub 2012 Feb 24.

PMID:
22362118
14.

Mutation of FLT3 gene in acute myeloid leukemia with normal cytogenetics and its association with clinical and immunophenotypic features.

Chauhan PS, Bhushan B, Mishra AK, Singh LC, Saluja S, Verma S, Gupta DK, Mittal V, Chaudhry S, Kapur S.

Med Oncol. 2011 Jun;28(2):544-51. doi: 10.1007/s12032-010-9485-4. Epub 2010 Mar 31.

PMID:
20354824
15.

Prognostic impact of white blood cell count in intermediate risk acute myeloid leukemia: relevance of mutated NPM1 and FLT3-ITD.

de Jonge HJ, Valk PJ, de Bont ES, Schuringa JJ, Ossenkoppele G, Vellenga E, Huls G.

Haematologica. 2011 Sep;96(9):1310-7. doi: 10.3324/haematol.2011.040592. Epub 2011 May 23.

16.

TET2 mutations in cytogenetically normal acute myeloid leukemia: clinical implications and evolutionary patterns.

Damm F, Markus B, Thol F, Morgan M, Göhring G, Schlegelberger B, Krauter J, Heuser M, Bernard OA, Ganser A.

Genes Chromosomes Cancer. 2014 Oct;53(10):824-32. doi: 10.1002/gcc.22191. Epub 2014 Jun 5.

PMID:
24898826
17.

Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).

Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, Ehninger G.

Blood. 2006 May 15;107(10):4011-20. Epub 2006 Feb 2.

18.

Fragment length analysis screening for detection of CEBPA mutations in intermediate-risk karyotype acute myeloid leukemia.

Fuster O, Barragán E, Bolufer P, Such E, Valencia A, Ibáñez M, Dolz S, de Juan I, Jiménez A, Gómez MT, Buño I, Martínez J, Cervera J, Montesinos P, Moscardó F, Sanz MÁ.

Ann Hematol. 2012 Jan;91(1):1-7. doi: 10.1007/s00277-011-1234-z. Epub 2011 May 3.

PMID:
21538063
19.
20.

Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia.

Marková J, Michková P, Burčková K, Březinová J, Michalová K, Dohnalová A, Maaloufová JS, Soukup P, Vítek A, Cetkovský P, Schwarz J.

Eur J Haematol. 2012 Feb;88(2):128-35. doi: 10.1111/j.1600-0609.2011.01716.x. Epub 2011 Nov 17.

PMID:
21967546
Items per page

Supplemental Content

Write to the Help Desk